HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety and effectiveness of the combination of 30Gy/5fx HSRT
and 20Gy/10fx IMRT adjuvant therapy. The total biological effective dose (BED) of the PTV is
72 Gy in a ratio of alpha/beta ratio of 3, which equals to the conventional 60Gy/30fx
treatment. This study can provide evidence for future non-inferiority phase III randomized
controlled trials. The abbreviated course of radiotherapy can reduce the treatment time by
half, benefit patients, and utilize the health resource.